39 related articles for article (PubMed ID: 30312216)
1. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
2. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
3. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
Chandekar KR; Satapathy S; Bal C
Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
[TBL] [Abstract][Full Text] [Related]
4. Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
Laschinsky C; Theurer S; Herold T; Rawitzer J; Weber F; Herrmann K; Brandenburg T; Führer-Sakel D; Fendler WP; Weber M
J Nucl Med; 2023 Dec; 64(12):1865-1868. PubMed ID: 37884333
[TBL] [Abstract][Full Text] [Related]
5. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
[TBL] [Abstract][Full Text] [Related]
6. Clinical factors for choosing active surveillance: an analysis of papillary thyroid microcarcinoma patients with recurrence.
Won HR; Kim MG; Kim MS; Chang JW; Koo BS
Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37992297
[TBL] [Abstract][Full Text] [Related]
7. Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy.
Boucai L; Saqcena M; Kuo F; Grewal RK; Socci N; Knauf JA; Krishnamoorthy GP; Ryder M; Ho AL; Ghossein RA; Morris LGT; Seshan V; Fagin JA
Clin Cancer Res; 2023 Apr; 29(8):1620-1630. PubMed ID: 36780190
[TBL] [Abstract][Full Text] [Related]
8. Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study.
Boucai L; Ptashkin RN; Levine RL; Fagin JA
Clin Endocrinol (Oxf); 2023 Jul; 99(1):122-129. PubMed ID: 37088956
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of
Rashid FA; Munkhdelger J; Fukuoka J; Bychkov A
Gland Surg; 2020 Oct; 9(5):1878-1900. PubMed ID: 33224863
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma.
Galuppini F; Fassan M; Bertazza L; Barollo S; Cascione L; Watutantrige-Fernando S; Lazzarin V; Simonato P; Vianello F; Rugge M; Mian C; Pennelli G
Cancer Manag Res; 2019; 11():7845-7855. PubMed ID: 31692513
[TBL] [Abstract][Full Text] [Related]
11. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract][Full Text] [Related]
12. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
13. BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases.
Shen G; Kou Y; Liu B; Huang R; Kuang A
Clin Nucl Med; 2018 Jul; 43(7):e215-e219. PubMed ID: 29762246
[TBL] [Abstract][Full Text] [Related]
14. Association of BRAF
Attia AS; Hussein M; Issa PP; Elnahla A; Farhoud A; Magazine BM; Youssef MR; Aboueisha M; Shama M; Toraih E; Kandil E
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555268
[TBL] [Abstract][Full Text] [Related]
15. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis.
Chen Y; Sadow PM; Suh H; Lee KE; Choi JY; Suh YJ; Wang TS; Lubitz CC
Thyroid; 2016 Feb; 26(2):248-55. PubMed ID: 26671072
[TBL] [Abstract][Full Text] [Related]
16. The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
Shen G; Kou Y; Liu B; Huang R; Kuang A
Nucl Med Commun; 2019 Jan; 40(1):8-13. PubMed ID: 30312216
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
